ProPhase Labs

ProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare products and dietary supplements. It operates through the Diagnostic Services and Consumer Products segment. The Diagnostic Services segment includes COVID-19 and other diagnostic testing services. The Consumer Products segment consists of the manufacturing, retail customers, and personal genomics products and services. The company was founded by Guy J. Quigley and Charles A. Phillips in July 1989 and is headquartered in Garden City, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

ProPhase Labs achieves record revenues, Nebula Genomics poised for growth

ProPhase Labs delivered strong financial performance in 2022, showcasing a successful transformation and diversification strategy.
The company's subsidiaries, particularly Nebula Genomics and BE-Smart, offer significant growth potential and differentiation in their respective markets.
While challenges like declining COVID testing trends and financial impacts exist, strategic opportunities and efficient management position ProPhase Labs for continued success.

ProPhase Labs prioritizes value-building over earnings, eyes global growth

ProPhase Labs is strategically focusing on long-term value creation through its diverse business segments.
While facing challenges in COVID testing and profitability, the company is optimistic about revenue growth from key assets.
Opportunities in precision medicine, cancer compounds, and global expansion present avenues for future growth.

ProPhase Labs shifts focus to genetic testing, eyes global expansion

ProPhase Labs is strategically pivoting towards genetic testing with Nebula Genomics, focusing on advanced laboratory capabilities and potential revenue generation. Despite revenue declines in Q2, the company remains optimistic about future growth prospects and is actively exploring financing options for expansion.

ProPhase Labs anticipates substantial growth with innovative healthcare solutions

ProPhase Labs is strategically positioned for growth with strong demand for its subsidiaries and innovative healthcare solutions in development.
While facing challenges in market conditions and revenue guidance, the company's focus on expansion and efficiency drives optimism for future performance.
Opportunities lie in revenue and profitability increases, potential IPOs, and advancements in esophageal cancer testing techniques and therapeutics.
Investors are encouraged to consider the long-term potential of ProPhase Labs as it navigates challenges and capitalizes on growth prospects.

ProPhase Labs excels in Q4, eyes revenue growth and strategic partnerships

ProPhase Labs showcased strong historical performance, profitable business segments, and strategic growth initiatives. The company is poised for substantial revenue growth through key contracts, innovative product offerings, and expansion into new markets. Challenges in short-term profitability and regulatory restrictions are being addressed while focusing on long-term value creation and growth potential.

ProPhase Labs (PRPH) reports strong performance and explores strategic opportunities

ProPhase Labs (PRPH) showcased strong historical performance, highlighted key initiatives like Pharmaloz and Nebula Genomics, and emphasized the potential for liquidity events. Challenges include revenue growth uncertainty and transparency concerns over share count increase.

ProPhase Labs strategizes for growth amidst seasonality and liquidity concerns

ProPhase Labs is navigating mixed performance with a focus on strategic initiatives, liquidity management, and maximizing shareholder value.
The company's strengths lie in its leadership team, growth potential in precision medicine, and plans for mitigating seasonality in revenue streams.
Challenges include seasonality impact, liquidity concerns, and the need for successful execution of strategic alternatives for Pharmaloz.
Opportunities exist in partnerships for Pharmaloz, growth potential in precision medicine, and anticipated revenue growth in the upcoming quarters.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GARDEN CITY, NY, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics and diagnostics company, today announced the pricing of its underwritten public offering of 4,170,000 shares of common stock. Each share of common stock is being sold at a public offering price of $0.72 per share, for gross proceeds of approximately $3 million, before deducting underwriting discounts, and offering expenses. All of the shares are being offered by the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 625,500 shares of common stock at the public offering price less discounts, to cover over-allotments. The offering is expected to close on November 12, 2024, subject to satisfaction of customary closing conditions.

ProPhase Labs Announces Pricing of Public Offering of Common Stock

Projections for Pharmaloz Manufacturing: Approximately $16-17 Million in Revenue, $6-7 Million in Pre-Tax Earnings for 2025

ProPhase Labs Announces Positive Updates on Strategic Initiatives Company Anticipates Multiple Liquidity Events in H1 2025

NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, an equity research firm with a focus on small capitalization public companies has released an Update Note on ProPhase Labs Inc. (NASDAQ: PRPH). The update note includes information on the ProPhase's business model, services, industry, financial results, valuation, and risks and contains our most recent research and analysis of the company.

Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)

GARDEN CITY, NY, Aug. 19, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today announced that it will be presenting at the Virtual Investor Summit Microcap Event. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.

ProPhase Labs to Present at August 20th Virtual Investor Summit Microcap Event

ProPhase Labs, Inc. (NASDAQ:PRPH ) Q2 2024 Earnings Conference Call August 14, 2024 11:00 AM ET Company Participants Noella Alexander-Young - Renmark Financial Communications Ted Karkus - Chief Executive Officer Conference Call Participants Hunter Diamond - Diamond Equity Noella Alexander-Young Hello and good morning, everyone. Welcome to today's presentation.

ProPhase Labs, Inc. (PRPH) Q2 2024 Earnings Call Transcript

GARDEN CITY, NY, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), announced today that they will be presenting second quarter 2024 financial results on a virtual conference call hosted by Renmark Financial on August 14, 2024 at 11:00 am EDT. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.

PROPHASE LABS INC. TO PRESENT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 14

PMI Revenues and Earnings Projected to Grow Significantly in the Second Half of 2024 and Full Year 2025. New Strategic Initiatives for PMI Create Significant Opportunities for Liquidity and Value Creation Garden City, NY, July 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported that Pharmaloz Manufacturing, Inc. (“PMI”), its wholly-owned subsidiary, is projecting significant revenues and earnings growth for the second half of 2024 and the entire year of 2025.

ProPhase Labs Announces Update on Pharmaloz Manufacturing, Inc. Progress

ProPhase Labs is a diversified biotech company with profitable existing product lines and plans for expansion. The company's subsidiary, Nebula Genomics, offers whole genome sequencing and plans to leverage the data for AI applications.

ProPhase Labs: Hidden Gem With An AI Kicker

ProPhase Labs, Inc. (NASDAQ:PRPH ) Q1 2024 Earnings Conference Call May 9, 2024 11:00 AM ET Company Participants Noella Alexander-Young - Renmark Financial Communications Ted Karkus - Chief Executive Officer Conference Call Participants Noella Alexander-Young Welcome to today's presentation. My name is Noella Alexander-Young, Virtual Event Moderator here at Renmark Financial Communications.

ProPhase Labs, Inc. (PRPH) Q1 2024 Earnings Call Transcript

Pharmaloz Manufacturing explores strategic alternatives, including potential sale. Company announces major strategic AI initiative, Project ZenQ-AI, leveraging its massive global genomics database and patented discoveries in its BE-Smart Esophageal Cancer Diagnostic Test.

ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives. - Updated

ProPhase Labs (PRPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ProPhase Labs, Inc. (PRPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Garden City, NY, April 25, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a biopharma, genomics and diagnostics Company, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 at 11:30 am PST, 2:30 pm EST. Ted Karkus, CEO, will be hosting the presentation and answering questions at the conclusion.

ProPhase Labs to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024

Leveraging ProPhase Labs' AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development.

ProPhase Labs Unveils Project ZenQ-AI

Garden City, NY, April 10, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported its progress on the commercialization of its breakthrough BE-Smart test for esophageal cancer. The Company is aiming for commercial launch in the second half of 2024.

ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024

Garden City, NY, April 01, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biopharma, genomics, and diagnostics company, today announced that it has granted an inducement stock option to purchase up to 50,000 shares of the Company's common stock to Lance Bisesar, who recently joined the Company as Controller. This award was made in accordance with the employment inducement award exemption provided by Nasdaq Rule 5635(c)(4) and was therefore not awarded under the Company's stockholder approved equity plan. The option award will vest as follows, contingent upon continued service: 25% will vest on each of the next four anniversaries of the grant date. The options will have a strike price of $6.20 per share and will be exercisable for a period of 7 years.

ProPhase Labs Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ProPhase Labs, Inc. (PRPH) Q4 2023 Earnings Call Transcript

Nebula Genomics secures major international B2B deal – Additional significant B2B deals in final stages Ahead of schedule, Pharmaloz Manufacturing accelerates capacity expansion – set for rapid revenue and profit growth Completes full transition and right sized operation in Q4 from clinical lab to cutting edge genomics lab Company to hold a conference call Friday March 15, 2024, at 11:00 AM ET Garden City, NY, March 15, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biopharma, genomics, and diagnostics company, today reported its financial and operational results for the full-year ended December 31, 2023. The end of 2023 marked a period of significant capacity expansion and growth for Pharmaloz Manufacturing Inc. (PMI) as well as a pivotal transformation for the Company, transitioning from a clinical laboratory framework to a leader in whole genome sequencing.

ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic Initiatives

Smart Share Global

In the volatile world of trading and investing, where fortunes can be made or lost in the blink of an eye, two companies caught the attention of Wall Street despite their recent struggles over the last year.

Down 34% and 57%, Wall Street Says These 2 Stocks Will Gain 230%

GARDEN CITY, NY, March 08, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), announced today that they will be presenting full year 2023 financial results on a virtual conference call hosted by Renmark Financial on March 15, 2024 at 11:00 am EDT. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.

PROPHASE LABS TO PRESENT 2023 YEAR END FINANCIAL RESULTS ON MARCH 15, 2024

Commercialization of Equivir anticipated after second trial is completed in Q2, 2024 Garden City, NY, Feb. 14, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics and diagnostics company, today announced positive preliminary results from its Equivir dietary supplement comprehensive trial. Preliminary results indicate that this innovative OTC dietary supplement has the potential to support and maintain immunity, which – if confirmed at the end of the clinical trial program – may help reduce both the frequency and severity of upper respiratory illnesses including the common cold, flu, and Covid-19.

ProPhase Labs Announces Preliminary Positive Results for Dietary Supplement Equivir

Pharmaloz Wins Two New Contracts in January that are Anticipated to Significantly Increase Lozenge Revenues and Profitability Company in Late-Stage Discussions with Two Additional Large Global Brands Which, if Consummated, Could more than Triple Run-Rate of Revenues Before Year-End 2024

Pharmaloz Manufacturing Accelerates Expansion, Improves Pricing, Boosts Profitability and Secures New Contracts

ProPhase Labs, Inc. (NASDAQ:PRPH ) Q3 2023 Earnings Conference Call November 9, 2023 11:00 AM ET Company Participants Ted Karkus - Chairman and CEO Conference Call Participants Adam Waldo - Lismore Partners Yi Chen - H.C. Wainwright Hunter Diamond - Diamond Equity Dennis Waldman - Barrett Productions Operator Good day and welcome the ProPhase Labs Incorporated Third Quarter 2023 Financial Results and Corporate Update.

ProPhase Labs, Inc. (PRPH) Q3 2023 Earnings Call Transcript

GARDEN CITY, NY, Nov. 02, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics, therapeutics and diagnostics company, will hold a conference call on Thursday, November 9, 2023, at 11:00 a.m. Eastern time to discuss its results for the third quarter ended September 30, 2023 and provide a business update. A press release detailing these results will be issued prior to the call.

ProPhase Labs to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 9, 2023 at 11:00 a.m. Eastern Time

Pharmaloz plan is to build capacity with a goal to attain a revenue run-rate of $60 to $80 million by year-end 2024, with 20-25% pre-tax net margins and a goal for additional growth thereafter.

ProPhase Labs Announces Substantial Growth Expectations for Pharmaloz Manufacturing Subsidiary due to Skyrocketing Demand for Pharmaloz Output.

GARDEN CITY, NY, Oct. 12, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics, therapeutics and diagnostics company, today announced it will be participating in The ThinkEquity Conference, which will take place on October 19, 2023 at The Mandarin Oriental Hotel in New York.

News for ProPhase Labs Stock (PRPH)